CTIS.eu › Cities › Italy › Meldola
Meldola
Italy
447 total trials
206 recruiting
2022-501417-31-00
5
High-risk Resected Melanoma
2024-515555-38-01
4
NON SMALL CELL LUNG CANCER
2024-516436-10-00
5
Acute myeloid leukemia
2024-518026-32-00
5
Invasive Breast Cancer
2024-518225-15-00
4
Myelofibrosis
2024-518386-95-02
4
Non small-cell lung cancer
2024-519010-31-00
3
High-Risk, Surgically Resectable Melanoma
2024-519031-42-00
5
pancreatic ductal adenocarcinoma
2024-519087-41-00
5
Breast cancer is the most common form of cancer among women in North A
2024-519106-12-00
4
Patients with anaplastic lymphoma kinase positive (ALK+) locally advan
2024-519183-40-00
4
NET
2024-519504-27-00
5
Relapsed Refractory Multiple Myeloma
2024-519519-32-00
4
urothelial cancer
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
2024-520081-65-00
4
NSCLC non-small cell lung cancer
2025-520565-51-00
5
small cell lung cancer
2025-521209-42-00
6
advanced colorectal cancer with wild-type RAS and right primary tumour
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
2025-521583-35-00
4
non-small cell lung cancer (NSCLC)
2025-521587-35-00
5
Metastatic colorectal cancer
2025-521666-10-01
4
Mantle Cell Lymphoma
2025-522084-15-00
10
metastatic NSCLC patients
2025-522288-13-00
4
Patients with pretreated extensive-stage small cell lung cancer (ES-SC
Showing 1–24 of 447 trials